Sesen Bio, Inc.
(NASDAQ GM: SESN)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Sesen Bio, Inc. ("Sesen") on behalf of stockholders. A class action complaint has been filed against Sesen. The complaint alleges that defendants materially misled the public by failing to disclose material risks to Vicineum's approval. Specifically, defendants failed to disclose to investors that: (i) Sesen's clinical trials showed that Vicineum leaked out from the bladder into the body, interacting with non-cancerous cells and leading to side effects including potentially fatal drug-induced liver injury; (ii) the VISTA clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as "major"; (iii) three of Sesen's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (iv) Sesen had submitted the tainted data in connection with applications for regulatory approval to market Vicineum; and (v) the European Medicines Agency had identified and raised serious concerns about Vicineum and the VISTA trial and conveyed such concerns to Sesen Bio.